| Name | Title | Contact Details |
|---|
Premera is a Mountlake Terrace, WA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Synchem is a Elk Grove Village, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Bioneer is a Alameda, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
RenovoRx is a clinical-stage biopharmaceutical company focused on fighting cancer through the localized treatment of difficult to treat tumors via our proprietary RenovoRx Trans-Arterial Micro-Perfusion (RenovoTAMP®) therapy platform. RenovoTAMP utilizes approved chemotherapeutics with validated mechanisms of action and well-established safety and side effect profiles, with the goal of increasing their efficacy, improving their safety, and widening their therapeutic window. Our lead product candidate, RenovoGem, is a combination of gemcitabine and our patented delivery system regulated by the FDA as a novel oncology drug product to treat unresectable locally advanced pancreatic cancer (LAPC). Targeted therapy via RenovoTAMP platform safely and without transmission to non-targeted areas, is our primary focus. RenovoRx`s patent portfolio currently includes seven issued US patents and one European patent for ourtechnology with several additional patents pending in the US, Europe, and Asia. After demonstrating a median survival of 27.9 months in Phase 1/2 clinical trials vs. 12-15 months reported in historical studies for this patient population, RenovoRx secured two separate Orphan Drug Designations from the FDA for intra-arterial gemcitabine: pancreatic cancer and bile duct cancer (cholangiocarcinoma). This therapy is being further studied in the currently enrolling Phase 3 TIGeR-PaC clinical trial in pancreatic cancer and has a primary endpoint of overall survival and several secondary endpoints, including quality of life. The Phase 3 TIGeR-PaC clinical trial is enrolling unresectable locally advanced pancreatic cancer patients (LAPC) in the United States.
TissueVision Inc. (TVI) is a multi-disciplinary life sciences company offering 3D tissue imaging and analysis solutions for the research market. Our powerful Serial Two-Photon Plus (STP²) platform features stunning high-resolution multispectral datasets and analysis pipelines that create reliable 3D tissue models. The indexed histological sections produced during the STP² process can be further investigated with secondary analyses that run the gamut from standard histological stains to advanced spatial genomics. The final result is rich, multiplexed 3D models that deliver actionable and quantitative results. TVI provides project design, GLP-like documentation, including full protocol and report generation, and quality control review measures of all study-related materials. TVI is a solution provider to help answer research questions in a variety of therapeutic areas, including neuroscience, cancer, neurodegeneration, ophthalmology, and dermatology.